Evidence map›Paper›PMID 36717776›Full record

ArticleBMC microbiology2023

Human liver microbiota modeling strategy at the early onset of fibrosis.

Camille Champion, Radu M Neagoe, Maria Effernberger, Daniela T Sala, Florence Servant, Jeffrey E Christensen, Maria Arnoriaga-Rodriguez, Jacques Amar, Benjamin Lelouvier, Pascale Loubieres and 11 more

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 5 countries.

Camille Champion *Institut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Radu M Neagoe *Second Department of Surgery, Emergency Mureş County Hospital, University of Medicine Pharmacy, Science and Technology "George Emil Palade" Tîrgu Mures, Târgu Mureș, Romania. neagoerm@gmail.com.
Maria EffernbergerDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria.
Daniela T SalaSecond Department of Surgery, Emergency Mureş County Hospital, University of Medicine Pharmacy, Science and Technology "George Emil Palade" Tîrgu Mures, Târgu Mureș, Romania.
Florence ServantVAIOMER, 516 Rue Pierre Et Marie Curie, 31670, Labège, France.
Jeffrey E ChristensenInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Maria Arnoriaga-RodriguezDepartment of Diabetes, Endocrinology and Nutrition, University Hospital of Girona 'Dr Josep Trueta', Girona, Spain.
Jacques AmarInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Benjamin LelouvierVAIOMER, 516 Rue Pierre Et Marie Curie, 31670, Labège, France.
Pascale LoubieresInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Vincent AzalbertInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Matthieu MintyInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Charlotte ThomasInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Vincent Blasco-BaqueInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France.
Fabrice GamboaInstitut de Mathématiques de Toulouse, Université Paul Sabatier, Toulouse, France.
Herbert TilgDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria.
Marina CardelliniDepartment of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Massimo FedericiDepartment of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Jose-Manuel Fernández-RealDepartment of Diabetes, Endocrinology and Nutrition, University Hospital of Girona 'Dr Josep Trueta', Girona, Spain.
Jean Michel LoubesInstitut de Mathématiques de Toulouse, Université Paul Sabatier, Toulouse, France. loubes@math.univ-toulouse.fr.
Rémy BurcelinInstitut National de La Santé Et de La Recherche Médicale (INSERM), Toulouse, France. remy.burcelin@inserm.fr.
Université Toulouse III - Paul Sabatier · FRInserm · FRToulouse Mathematics Institute · FRUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversity of Rome Tor Vergata · ITCentro de Investigación Biomédica en Red · ESInnsbruck Medical University · ATInstitut des Maladies Métaboliques et Cardiovasculaires · FRInstitut d'Investigació Biomèdica de Girona · ESUniversität Innsbruck · AT

Funding

VAIOMER SAS 6869/12.06.2014
6 · The paper itself

Abstract

backgroundGut microbiota is involved in the development of liver diseases such as fibrosis. We and others identified that selected sets of gut bacterial DNA and bacteria translocate to tissues, notably the liver, to establish a non-infectious tissue microbiota composed of microbial DNA and a low frequency live bacteria. However, the precise set of bacterial DNA, and thereby the corresponding taxa associated with the early stages of fibrosis need to be identified. Furthermore, to overcome the impact of different group size and patient origins we adapted innovative statistical approaches. Liver samples with low liver fibrosis scores (F0, F1, F2), to study the early stages of the disease, were collected from Romania(n = 36), Austria(n = 10), Italy(n = 19), and Spain(n = 17). The 16S rRNA gene was sequenced. We considered the frequency, sparsity, unbalanced sample size between cohorts to identify taxonomic profiles and statistical differences.

resultsMultivariate analyses, including adapted spectral clustering with L1-penalty fair-discriminant strategies, and predicted metagenomics were used to identify that 50% of liver taxa associated with the early stage fibrosis were Enterobacteriaceae, Pseudomonadaceae, Xanthobacteriaceae and Burkholderiaceae. The Flavobacteriaceae and Xanthobacteriaceae discriminated between F0 and F1. Predicted metagenomics analysis identified that the preQ0 biosynthesis and the potential pathways involving glucoryranose and glycogen degradation were negatively associated with liver fibrosis F1-F2 vs F0.

conclusionsWithout demonstrating causality, our results suggest first a role of bacterial translocation to the liver in the progression of fibrosis, notably at the earliest stages. Second, our statistical approach can identify microbial signatures and overcome issues regarding sample size differences, the impact of environment, and sets of analyses.

trial registrationTirguMECCH ROLIVER Prospective Cohort for the Identification of Liver Microbiota, registration 4065/2014. Registered 01 01 2014.

Indexed as

Liver CirrhosisMicrobiotaDNA, BacterialFibrosisHumansProspective StudiesRNA, Ribosomal, 16SDNA, BacterialRNA, Ribosomal, 16SBiomathematicsLiver diseasesMetabolic diseaseMicrobiotaTissue microbiota

Identifiers

PMID36717776
PMCPMC9885577
OpenAlexW4318475686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.